Home / Poster / Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A4*22 and/or CYP3A5*3) and a renal transplant population

ポスター

Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A422 and/or CYP3A53) and a renal transplant population

Essentials of Model-informed Drug Development in Oncology

ブログ

Non-Animal Navigator™: 動物実験の削減、改善、代替を実現する戦略とAIを活用したシミュレーション

製品紹介資料

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

ウェビナー

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

事例紹介

Powered by Translations.com GlobalLink Web Software

Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A422 and/or CYP3A53) and a renal transplant population

Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A422 and/or CYP3A53) and a renal transplant population

Essentials of Model-informed Drug Development in Oncology

Non-Animal Navigator™: 動物実験の削減、改善、代替を実現する戦略とAIを活用したシミュレーション

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

メルマガ登録

クイックアクセス

ソリューション

お問合せ